The stock is down more than 50% from its 52-week high.
New data indicate that its cell therapy could soon find a larger market.
These biotech stocks have just launched their first products.
These four small-cap stocks scan as deeply undervalued right now.
Investors are misunderstanding when the biopharma company's flagship drug will begin generating meaningful reportable revenue.
Iovance Biotherapeutics: Q1 Earnings Snapshot
The time to jump into a red-hot growth prospect is usually right now...before any more investors identify the opportunity.
Is this rising healthcare stock a good buy right now?
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential.
Catalysts lie ahead for both of these companies.